Danaher

Danaher makes instruments, consumables, software and services for life science research, drug manufacturing and medical diagnostics. Its main businesses include Cytiva and Pall, which sell bioprocessing products to companies that make biologic drugs, Beckman Coulter, Leica and Cepheid in diagnostics, and Masimo, a patient monitoring company it bought in June 2026. Most of its revenue comes from consumables, such as reagents, chromatography resins, filters and test cartridges, which customers buy again and again after they install an instrument.

Revenue was $6.3 billion in Q2 2026. It runs its businesses with the Danaher Business System, a set of tools for continuous improvement. Its co-founders, Steven and Mitchell Rales, lead the board, and Julie Sawyer Montgomery became President and CEO on October 1, 2026.

The market prices Danaher with a discount because its growth is slow after the pandemic boom, and its recovery depends on events it does not control. Core revenue grew 0.5% in Q1 2026 and 3.0% in both Q2 and Q3 2026. In October 2026, Danaher lowered its 2026 core growth outlook to about 2.5%, from 3% to 4%, because respiratory test sales are weaker. Large bioprocessing customers moved the timing of shipments in Q2 2026, China's volume-based procurement program cut diagnostics prices, and respiratory test sales at Cepheid change with each flu season.

The $9.8 billion purchase of Masimo in June 2026 also raised debt, and the CEO changed on October 1, 2026. For the gap to close, three things must be true. Core revenue growth must reach a mid-single-digit rate in 2027. Without respiratory tests, core growth was 5.5% in Q3 2026, and Danaher guides 4% to 5% for Q4.

Bioprocessing growth, which reached the upper end of mid-single digits in Q3 2026, must continue. Masimo must add to earnings while Danaher repays the commercial paper that funded it. The next test is the Q4 2026 report with the 2027 guidance, expected in late January 2027. If growth speeds up as planned, the gap can close over the next three to five quarters.

If bioprocessing customers delay orders again, or respiratory sales stay weak, the discount can last longer.

1. Oct 21, 2026Failed

   Q3 2026 results: core growth and bioprocessingA pass is core revenue growth at or above the guided 2% to 3% with bioprocessing revenue growth; a fail is core growth below 2% or a lower 2026 guidance.Outcome: Core revenue grew 3.0% and bioprocessing grew, but Danaher lowered its 2026 core growth outlook to about 2.5% from 3% to 4%, while it raised its adjusted EPS guidance.
2. Jan 21, 2027 · est.Pending

   Q4 2026 results and 2027 guidanceA pass is a Q4 exit at mid-single-digit core growth and 2027 guidance at that rate; a fail is low-single-digit 2027 guidance.
3. Q2 2027 · est.Pending

   Masimo integration and debt reductionA pass is Masimo growth inside Diagnostics and lower commercial paper by mid-2027; a fail is a Masimo impairment or higher debt.

Every passed and failed checkpoint across all picks

• October 21, 2026Danaher reported Q3 2026 results. Revenue grew 8.5% to $6.55 billion, and core revenue grew 3.0%, at the top of the 2% to 3% guidance. Without respiratory testing, core revenue grew 5.5%. Bioprocessing core sales grew near the upper end of mid-single digits. Adjusted EPS grew 11.5% to $2.11, and free cash flow was $1.6 billion. Danaher raised its 2026 adjusted EPS guidance to $8.57 to $8.62. It lowered its 2026 core revenue growth outlook to about 2.5%, from 3% to 4%, and expects about 3% in Q4 because of a respiratory headwind of about 1.5 points. The stock closed 4.3% higher that day.
• October 14, 2026Danaher announced a collaboration with NVIDIA on autonomous science. On October 7, it announced a new AI-powered autonomous lab for life sciences research.
• October 9, 2026Danaher added two directors, Daniel Comas, its former CFO, and Robert Hershberg, the former CEO of HilleVax, so the board grew to 13 members. On the same day, Steven and Mitchell Rales gave up, for no payment, the restricted stock units for 500,000 shares each that the company granted them on August 4, 2026.

• Bioprocessing demand depends on the plans of a few large drug makers. In Q2 2026, some large commercial customers moved the timing of shipments, and this cut revenue even though orders grew. A new delay would slow the recovery that management expects.
• China's volume-based procurement program cuts the prices of diagnostic tests. It lowered Diagnostics prices by 1.5% in Q2 2026, and core sales in China fell in Diagnostics.
• The Masimo purchase raised debt from $18.4 billion at December 31, 2025 to $26.5 billion at September 25, 2026, and $4.7 billion of it is short-term commercial paper. Danaher must also integrate Masimo and its legal cases, such as the patent case against Apple.
• A new CEO took over on October 1, 2026, and the board added two directors in October 2026. A new leader can change priorities and the pace of acquisitions.
• Respiratory test sales at Cepheid change with each flu and COVID-19 season, so quarterly revenue can miss expectations. A shareholder class action about past bioprocessing revenue statements has a settlement, which the court approved in a preliminary way on June 1, 2026; Danaher does not expect a material impact.

Debt is the carrying value of notes payable and long-term debt at September 25, 2026. It includes $4.7 billion of euro commercial paper, which matures within a year but which Danaher shows as long-term debt because its credit lines can refinance it. Read more